Research progress on the role of butyrylation modification in malignant tumors

doi:10.16352/j.issn.1001-6325.2025.11.1496

Abstract

Abstract: Butyrylation (Kbu), as an important post-translational modification (PTM) of proteins, precisely regulates various biological behaviors of tumor cells by modulating the structure and function of proteins. Abnormal butyrylation promotes tumor cell proliferation and migration by regulating protein stability, enzyme activity, cell signaling pathways, chromatin structure and gene expression, and further participates in tumor occurrence and development. This review focuses on the role of butyrylation modification in the occurrence and development of various human tumors, aiming to summarize the research progress of butyrylation modification in the field of tumors, and to provide new directions for tumor treatment through the intervention strategies of butyrylation modification.

Key words: butyrylation, malignant tumor, post-translational modification

CLC Number:

R73-3

SHI Dongxue, WANG Ruihan, LYU Beibei, LIN Xiaoyan. Research progress on the role of butyrylation modification in malignant tumors[J]. Basic & Clinical Medicine, 2025, 45(11): 1496-1500.

References

[1] Shang S,Liu J,Hua F. Protein acylation: mechanisms,biological functions and therapeutic targets[J]. Signal Transduct Target Ther,2022,7: 396. doi:10.1038/s41392-022-01245-y.
[2] Zhu Z,Han Z,Halabelian L,et al. Identification of lysine isobutyrylation as a new histone modification mark[J]. Nucleic Acids Res,2021,49: 177-189.
[3] Dong H,Zhao Y,Bi C,et al. TmcA functions as a lysine 2-hydroxyisobutyryltransferase to regulate transcription[J]. Nat Chem Biol,2022,18: 142-151.
[4] Huang H,Tang S,Ji M,et al. P300-mediated lysine 2-hydroxyisobutyrylation regulates glycolysis[J]. Mol Cell,2018,70: 663-678.
[5] Huang H,Zhang D,Weng Y,et al. The regulatory enzymes and protein substrates for the lysine β-hydroxybutyrylation pathway[J]. Sci Adv,2021,7. doi:10.1126/sciadv.abe2771.
[6] Zhou T,Cheng X,He Y,et al. Function and mechanism of histone β-hydroxybutyrylation in health and disease[J]. Front Immunol,2022,13: 981285. doi:10.3389/fimmu.2022.981285.
[7] Dmitrieva-posocco O,Wong AC,Lundgren P,et al. β-hydroxybutyrate suppresses colorectal cancer[J]. Nature,2022,605: 160-165.
[8] Shahar N,Larisch S. Inhibiting the inhibitors: targeting anti-apoptotic proteins in cancer and therapy resistance[J]. Drug Resist Updat,2020,52: 100712. doi:10.1016/j.drup.2020.100712.
[9] He Y,Zheng CC,Yang J,et al. Lysine butyrylation of HSP90 regulated by KAT8 and HDAC11 confers chemoresistance[J]. Cell Discov,2023,9: 74. doi:10.1038/s41421-023-00570-y.
[10] Liao L He Y,Li SJ,et al. Lysine 2-hydroxyisobutyryla-tion of NAT10 promotes cancer metastasis in an ac4C-dependent manner[J]. Cell Res,2023,33: 355-371.
[11] Fioravanti R,Mautone N,Rovere A,et al. Targeting histone acetylation/deacetylation in parasites: an update (2017—2020)[J]. Curr Opin Chem Biol,2020,57: 65-74.
[12] Chen SH,Hsiao SY,Chang KY,et al. New insights into oral squamous cell carcinoma: from clinical aspects to molecular tumorigenesis[J]. Int J Mol Sci,2021,22. doi:10.3390/ijms22052252.
[13] Zhang Z,Xie H,Zuo W,et al. Lysine 2-hydroxyisobutyrylation proteomics reveals protein modification alteration in the actin cytoskeleton pathway of oral squamous cell carcinoma[J]. J Proteomics,2021,249: 104371. doi:10.1016/j.jprot.2021.104371.
[14] Xu G,Wang J,Wu Z,et al. SAHA regulates histone acetylation,butyrylation,and protein expression in neuro-blastoma[J]. J Proteome Res,2014,13: 4211-4219.
[15] Doll S,Urisman A,Oses-prieto A,et al. Quantitative proteomics reveals fundamental regulatory differences in oncogenic HRAS and isocitrate dehydrogenase (IDH1) driven astrocytoma[J]. Mol Cell Proteomics,2017,16: 39-56.
[16] Bray F,Laversanne M,Sung H,et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2024,74: 229-263.
[17] Zhang Z,Wang Y,Liang Z,et al. Modification of lysine-260 2-hydroxyisobutyrylation destabilizes ALDH1A1 expression to regulate bladder cancer progression[J]. iScience,2023,26: 108142. doi:10.1016/j.isci.2023.108142.
[18] Zheng RS,Chen R,Han BF,et al. Cancer incidence and mortality in China,2022[J]. Chin J Oncol,2024,46: 221-231.
[19] Lu Y,Li X,Zhao K,et al. Global landscape of 2-hydroxyisobutyrylation in human pancreatic cancer[J]. Front Oncol,2022,12: 1001807. doi:10.3389/fonc.2022.1001807.
[20] Tsuboi M,Herbst RS,John T,et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC[J]. N Engl J Med,2023,389: 137-147.
[21] Huang J,Liang L,Jiang S,et al. BDH1-mediated LRRC31 regulation dependent on histone lysine β-hydroxybutyry-lation to promote lung adenocarcinoma progression[J]. MedComm (2020),2023,4: e449. doi:10.1002/mco2.449.
[22] Xia C,Dong X,Li H,et al. Cancer statistics in China and United States,2022: profiles,trends,and determinants[J]. Chin Med J (Engl),2022,135: 584-590.
[23] Zhao LN,Yuan HF,Wang YF,et al. IFN-α inhibits HBV transcription and replication by promoting HDAC3-mediated de-2-hydroxyisobutyrylation of histone H4K8 on HBV cccDNA minichromosome in liver[J]. Acta Pharmacol Sin,2022,43: 1484-1494.
[24] Zhang H,Chang Z,Qin LN,et al. MTA2 triggered Rloop transregulates BDH1-mediated β-hydroxybutyryla-tion and potentiates propagation of hepatocellular carcinoma stem cells[J]. Signal Transduct Target Ther,2021,6: 135. doi:10.1038/s41392-021-00464-z.